Introduction
B-cell development originates in the bone marrow, where hematopoietic stem cell precursors commit to the B-cell lineage and immunoglobulin heavy-chain gene rearrangements occur. 1, 2 If rearrangement is successful, differentiation into the transitional B-cell compartment occurs. Cells that generate functional B-cell antigen receptors eventually leave the bone marrow and migrate to the spleen to complete their maturation process. 3, 4 The first B cells to arrive are referred to as transitional 1 (T1) B cells. 5, 6 T1 B cells are still subject to negative selection, where strong antigenic signals lead to apoptosis. In later transitional stages, some of the transitional B cells (transitional 2 [T2]) are allowed to develop into either mature follicular (FO) B cells, which can recirculate in the periphery, or marginal zone (MZ) B cells, which remain largely sessile. 7, 8 The B-cell activation factor receptor belonging to the tumor necrosis factor (TNF) superfamily (BAFF-R, BR3) provides critical survival signals to all splenic B-cell subsets. Targeted deletion of BAFF ligand or BAFF-R results in a partial block at the T1 to T2 transition, resulting in severe deficiency of mature B cells. 9, 10 BAFF initiates the noncanonical nuclear factor k-light-chain-enhancer of activated B cells (NF-kB) pathway via TRAF3, resulting in the stabilization of NF-kB-inducing kinase (NIK) and activation of a NF-kB essential modulator (NEMO)-independent IKK1 kinase complex. This mediates p100 processing, and nuclear translocation of RelB:p52 dimers. 11 Recent human studies have shown that patients with germ-line mutations in NFKB2 have immunodeficiency. In some of the patients, there is a loss of B cells. [12] [13] [14] It is likely that some of these B-cell developmental defects in the patients result from impaired BAFF-R signaling because of their nonprocessable p100. BAFF has also been reported to activate the canonical NF-kB pathway. 15, 16 Gene-targeted deletion of NFkB1 (p50), the primary binding partner of RelA and cRel, results in defective survival of B cells in response to BAFF. 17 Although neither cRel 2 /2 nor pathways may be redundant. 11 However, studies of a compound knockout of the 2 transcriptional activators that mediate canonical and noncanonical pathways, respectively, have not been reported.
Here, we show that only cRel and RelB show persistent activation in response to BAFF, and we therefore examine the physiological consequence of their deletion singly or in combination. We find that both provide survival signals, albeit via distinct gene expression programs, and that these complement each other, such that only the doubly deficient mouse shows severe B-cell developmental deficiencies. Deficiencies in mature B-cell subsets are based not solely on survival defects but also a block in differentiation block at the transitional T1 stage that is cell autonomous and can be observed in an ex vivo differentiation assay.
Materials and methods

Cell isolation and culture
Spleens were harvested from C57BL/6 wild type, cRel cells intravenously per mouse) into 2-to 3-month-old C57BL/6 or C57BL/6 x B6.SJL-Ptprc a F1 recipients. Before injection, recipient mice were lethally irradiated (1000 rads). Chimeric mice were analyzed 8 weeks after bone marrow reconstitution. Origin and composition of lymphoid cells was determined by Ly5.1 and Ly5.2 markers.
In vitro B-cell differentiation
In vitro differentiation was performed as previously described. 29 Briefly, bone marrow cells were cultured in complete Iscove modified Dulbecco medium with 20 ng/mL interleukin (IL) 7 for 3 to 4 days to enrich for IgM 1 transitional B cells. Cells were then washed twice with PBS to remove IL-7 and plated with 50 ng/mL recombinant murine BAFF. On subsequent days, cells were stained with anti-B220, IgM, and IgD antibodies to determine maturation.
Biochemical analysis
Electrophoretic mobility shift assays (EMSAs) were conducted as described previously 22, 30 and modified to include antibodies specific for RelA (Santa Cruz SC372), RelB (SC226), cRel (SC71), or a combination thereof. For EMSAs focusing on cRel-DNA binding activity, nuclear extracts were preincubated with RelA and RelB antibodies for 15 minutes on ice prior to addition of radiolabeled probe to ablate their specific DNA binding activities. Similarly, nuclear extracts were preincubated with RelA and cRel antibodies or RelB and cRel antibodies when RelB-or RelA-DNA binding activity was the focus, respectively (see Figure 1B ). Other antibodies used for immunoblotting were Akt (Cell Signaling Technology, CST#4691), phospho-Akt (Ser473) (CST#4060), nuclear factor of k light polypeptide gene enhancer in B-cells inhibitor (IkB) a (SC371), IkBe (SC7155), a-tubulin (SC26), NFkB1/p50 and NFkB2/p52 (Dr Nancy Rice), and Bclxl (Abcam, #ab256).
Transcriptome analysis
Total RNA was extracted from 50 ng/mL BAFF-stimulated wild-type B cells. Messenger RNA was isolated from 2 mg total RNA using oligo (dT) magnetic beads and fragmented at high temperature using divalent cations. Complementary DNA libraries were generated using the Illumina Truseq kits, and quantitation was performed using the Roche Light Cycler 480. Sequencing was performed on Illumina's HiSequation 2000, according to the manufacturer's recommendations and prepared for RNA-sequencing (RNA-seq) analysis by the Broad Stem Cell Research Center core facility at the University of California, Los Angeles. Reads were aligned to the mouse mm10 genome and RefSeq genes 31, 32 with Tophat. 33 Cufflinks CummRbund 34 was used to ascertain differential expression of genes. Gene differential FPKMs were obtained from the cuffdiff program in the Tuxedo RNA-seq analysis suite. RNA-seq data are deposited in the National Center for Biotechnology Information's Gene Expression Omnibus database (accession number GSE62559).
Results
BAFF induces persistent NF-kB RelB and cRel activities that have complementary roles in mediating B-cell survival
BAFF is known to engage 3 BLyS family receptors, namely, B-cell maturation antigen (BCMA), transmembrane activator and calciummodulating cyclophilin ligand-interactor protein (TACI), and BAFF-R (also known as BR3 or BLYS receptor), 35 and to activate several signaling pathways including the canonical and noncanonical NF-kB pathways, whose transcriptional effectors are RelA/cRel and RelB, respectively ( Figure 1A ).
We examined which NF-kB transcription factors are activated by BAFF in murine splenic B cells. We used a modified EMSA procedure in which antibodies are used to ablate 2 of 3 activationdomain-containing NF-kB family members ( Figure 1B ). Stimulation with BAFF ligand resulted in activation of RelA-, cRel-, and RelBcontaining dimers, but the time courses reveal that only cRel and RelB show persistent activation: RelA activity peaks at 1 hour and returns to basal levels within 8 hours. In contrast, cRel and RelB activities are not short lived, peaking at ;3 hours and persisting beyond 24 hours ( Figure 1C ). Repeated experimental analysis showed that these conclusions were statistically significant ( Figure 1D ).
Numerous studies have investigated which signaling pathways mediate BAFF's physiological functions, and these genetic knockout studies are summarized in Figure 1E . Of the 3 known BAFF-binding receptors, expression of BCMA is not observed in naive B-cell populations, and TACI deletion actually results in enhanced B-cell numbers and splenomegaly, whereas BAFF-R deletion phenocopies BAFF deletion in resulting in a near loss of peripheral B cells. 36 BAFF activates both canonical and noncanonical signaling branches of the NF-kB system, yet deficiencies in only canonical components (eg, NEMO, RelA/cRel) have been reported to result in defective B-cell development ( Figure 1E ). [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] However, the canonical pathway, and RelA in particular, is known to enable noncanonical signaling via NFkB2 and Relb expression 20, 21 ( Figure 1A) , suggesting that phenotypes observed in severe (D) cRel-dependent genes protect cells against cell death. Gene ontology analysis identifies distinct process terms for cRel-dependent vs RelB/cRel-dependent gene clusters. Whereas RelB/cRel-dependent clusters are significantly associated with terms describing metabolic processes, the cReldependent cluster shows overrepresentation of negative regulation of cell death/apoptosis. *P , .05; **P , .005; ***P , .001. Also see supplemental Figure 1 . (E) List of representative cRel-dependent and RelB/cRel-dependent genes identified as "negative regulators of cell death" and "metabolic process," respectively, by gene ontology analysis. B cells ( Figure 2C ). Of these, 127 genes were largely cRel dependent, as they showed lower BAFF-induced expression in both cRel 2/2 or Relb 2/2 cRel 2/2 B cells, and 162 were identified as RelB dependent in the context of cRel deficiency and may thus be described as potential RelB target genes. Interestingly, gene ontology analysis focusing on biological process terms identified a large number of receptorassociated and mitochondrial antiapoptotic regulators within the cReldependent cluster, whereas metabolic regulators were primarily identified in the RelB/cRel-dependent cluster ( Figure 2D -E). These data suggest that coordination of cRel and RelB activities by BAFF serves the expression of complementary sets of genes that ensure B-cell survival. Confirmatory reverse transcription-quantitative polymerase chain reaction showed that Bcl2 family members A1 and Bcl-xL required only cRel but not RelB for their expression, and the reduction is messenger RNA expression also resulted in a reduction in Bcl-xL protein (supplemental Figure 2) .
Compound deletion of RelB and cRel results in severe peripheral B-cell developmental defects
As RelB and cRel are critical for BAFF-mediated survival functions in vitro, we examined B-cell development in vivo in mice lacking RelB, cRel, or both. Using an established FACS strategy, 49 we confirmed that there is no defect in peripheral B-cell populations in cRel 2/2 mice and only a modest decrease in Relb 2/2 mice. However, we found a significant loss of mature B cells and an increase in the transitional compartment in double knockout mice ( Figure 3A) , whereas Tcell numbers were normal (supplemental Figure 3) . Distinguishing mature B-cell subsets, we confirmed previous reports that Relb 2/2 spleens were deficient in the MZ B-cell population 38 but now found that the double knockout mice generate significantly fewer FO B cells ( Figure 3B ; Table 1 ).
Dissection of transitional B-cell populations revealed an increased proportion of transitional T1 but not T2 cells ( Figure 3C ). T1 B cells are the initial class of B cells that give rise to the mature populations. 50 In addition, we examined the B-cell maturation in the bone marrow of the double knockout and found no discernible defect compared with wild type controls (supplemental Figure 4) . The increase in T1 B cells found in the double knockout mouse suggested to us that RelB and cRel are required not only for the survival of developing B cells but also for peripheral B-cell development per se. Although the Relb
developmental phenotype is not as severe as that caused by BAFF deficiency, the block at the T1 stage is reminiscent. 37 Further, histologic analysis corroborated these findings: in the Relb 2/2 cRel 2/2 spleen, the white pulp, although present, was not as dense ( Figure 3D ). The reduction in white pulp may be caused by reduced numbers of B cells in the spleen, as our FACS analysis suggested, or it may be a consequence of improper homing of the lymphocytes causing them to be dispersed throughout the spleen. To address this, we investigated the organization of B cells using immunofluorescence. Frozen sections of splenic tissue were stained with anti-CD3 and anti-B220 to identify the T-cell zone and B-cell zone, respectively. MOMA-1 (which stains MZ metallophilic macrophages) outlined the follicular rim surrounding the B-cell-rich zone. In agreement with our FACS data, the presence of B cells was greatly diminished in the Relb 2/2 cRel 2/2 spleen, as shown by the staining of B220 (red; Figure 3E ). We also observed that the characteristic ringlike structure of MOMA-1 staining (blue) is consistently less organized in the double knockout mouse, suggestive of a defective splenic architecture, which may 51, 52 or may not contribute to the B-cell development phenotype in the mutant mice.
B-cell intrinsic developmental defect in vivo
We studied whether the B-cell developmental phenotype is in fact B-cell intrinsic by generating mixed bone marrow chimeras, where bone marrow-derived hematopoietic stem cells from both wild type and mutant donor mice were injected into a lethally irradiated wild type or mutant recipient mice. To distinguish cells derived from either donor, we used the CD45 congenic marker system, in which donor cells expressed the CD45.1 or CD45.2 variant and recipient mice were CD45.1.2 (supplemental Figure 5A-B) .
Within this experimental system, we found that Relb
(CD45.2) hematopoietic stem cells were compromised in their development even when wild type recipients provided a normal milieu of architecture and soluble factors ( Figure 4A -B) akin to observations made in cRel-and RelB-deficient animals ( Figure 3A-C) . Again, the transitional B-cell populations are higher than the wild type controls, whereas FO populations were severely decreased and MZ B cells were undetectable ( Figure 4A-B) . As a reference, we also generated chimeras with RelB and cRel single knockout bone marrow cells, with no observable phenotype (supplemental Figure 5C-D A true cell intrinsic phenotype is expected to be recapitulated in an in vitro differentiation assay in which all nonintrinsic components are held equal. We employed an in vitro B-cell development assay system described previously. 11, 53 In this system, transitional B cells are generated from bone marrow progenitors in the presence of IL-7. The cytokine is washed away, then recultured with BAFF ligand ( Figure 5A ). Expression of B-cell markers CD23 and CD21 has been reported to be regulated by BAFF. 54 Further, FACS analysis suggested that RelB plays a role in CD21 expression ( Figure 3B) ; thus we used IgD and B220 as our primary developmental markers in these analyses. Exposure of wild type bone marrow cultures to BAFF for 4 days increased the fraction of IgD 1 cells relative to untreated controls, demonstrating BAFF's capacity to enhance B-cell development in vitro. In contrast, BAFF stimulation failed to increase the percentage of IgD 1 cells present in Relb 2/2 cRel 2/2 bone marrow cultures ( Figure 5B-C) . Even in the absence of BAFF, the numbers of IgD 1 cells were consistently lower in mutant cultures compared with wild type. In fact, the reduction in B-cell numbers in this assay may be dominated by a BAFF-dependent survival defect ( Figure 5D ). Together, these experimental results further illustrate the necessity of RelB and cRel in BAFF-mediated B-cell maturation. 
Deregulating NF-kB accelerates splenic B-cell development
Given that NF-kB RelB/cRel activities are required for B-cell maturation past the T1 stage (Figure 3 ), we asked whether elevated NF-kB might be sufficient to accelerate B-cell maturation. Compound deficiency of IkBa and IkBe leads to elevation of both constitutive and stimulus-responsive NF-kB activity, 55 inflammatory gene expression, and neonatal death. 56 We restored viability by introducing compound cRel and TNF deficiencies, leaving RelA and RelB deregulated, and examined the Bcell compartment. Although the total splenocytes count is lower in IkBa How does BAFF coordinately activate cRel and RelB? Three TNF receptor superfamily members bind BAFF, namely, BCMA, TACI, and BAFF-R (also known as BR3 or BLYS receptor), 51 with BAFF-R and TACI being expressed on peripheral B-cell subsets. 59 TACI activates canonical NF-kB signaling, 60 but TACIdeficient mice show no defect on B-cell development and B cells are capable of degrading IkBa in response to BAFF. 15 Our results are consistent with BAFF-R triggering both canonical, IkBa-mediated NF-kB signaling and also noncanonical, IkBd-mediated activation of RelA and cRel. As a key survival receptor, BAFF-R signaling maintains the B-cell pool. In contrast, TACI acts as a negative regulator of B-cell homeostasis, indirectly regulating peripheral B-cell numbers by competing for the amount of BAFF available for signaling through BAFF-R. 51 ,61 CD21 expression is reduced in the absence of RelB, and further decreased in the combined absence of RelB and cRel ( Figure 3B ). CD21 is known to be controlled by NF-kB-p52. 62, 63 Considering our data, CD21 is probably controlled by RelB:p52 complex during development, and cRel:p52 to a lesser extent (possibly providing compensation). Given that CD21 is essential in humoral immune response, 64, 65 it is likely RelB-deficient B cells will have impaired response to certain T-dependent antigens, especially complementtagged antigens. [66] [67] [68] Further functional studies are needed to address this.
Previous studies suggested that NF-kB regulates BAFF-R expression, 69, 70 although none of the NF-kB knockout studies cited in Figure 1E had examined BAFF-R expression. We examined BAFF-R expression in 2 ways: replicate RNA-seq did not show an expression defect in Relb 2/2 cRel 2/2 cells over wild type controls (supplemental Figure 6A ), thereby not corroborating transcriptional control by RelB/ cRel. However, by FACS, BAFF-R staining was reduced (supplemental Figure 6B ) and BAFF-responsive AKT phosphorylation (indicative of phosphatidylinositol 3-kinase activation) was also lower (supplemental Figure 6C) . Together, this suggests that the phenotype of Relb 2/2 cRel 2/2 B cells may in part be reinforced by a reduction in BAFF-R surface expression. As BAFF-R is transcribed at the normal rate, this reduction is not a direct consequence of RelB/cRel deficiency, but probably rather a consequence of cell-biological deficiencies that hinder B-cell maturation from the T1 stage. Further, although the loss of cRel and RelB reduces the amount of p100, as observed elsewhere, 71 BAFF-responsive noncanonical NFkB2/p100 degradation remained intact (supplemental Figure 6C) . I reviewed all previous requests. All are revised properly. Thanks! One co-author notified us one more thing after previous proof submission. It's very minor:
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